Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX660 in Relapsed or Refractory T-Cell Lymphoma
NCT04362007Phase 2Terminated
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jul 2020
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tolinapant in peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), adult T-cell leukemia-lymphoma (ATLL), sponsored by Otsuka Pharmaceutical Co., Ltd.. Started Jul 2020; status: terminated.
02
Drugs
tolinapant
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT04362007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04362007.